Orphan Synergy Europe - Pharma News

Orphan Synergy Europe - Pharma Aktie VALOR 25507187 / ISIN FR0012127173

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

26.03.25	OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
27.03.24	OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update (Businesswire)
19.01.24	OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook (Businesswire)
16.10.23	OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors (Businesswire)
27.09.23	OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update (Businesswire)
11.09.23	OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology (Businesswire)
06.07.23	OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: (Businesswire)
04.07.23	OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment (Businesswire)
20.06.23	OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
15.06.23	OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences (Businesswire)
27.04.23	OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update (Businesswire)
20.04.23	OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology (Businesswire)
18.04.23	OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio (Businesswire)
15.02.23	OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	952.60	1.88 %	K V
Swiss Re	142.05	1.10 %	K V
Kuehne+Nagel Int	161.15	1.10 %	K V
Lonza Grp	546.80	1.07 %	K V
UBS Group	30.91	0.91 %	K V
Sika	158.05	0.03 %	K V
Alcon	63.94	-0.03 %	K V
Swisscom	583.50	-0.34 %	K V
Novartis	104.64	-0.63 %	K V
Roche Hldg G	309.30	-1.15 %	K V